肿瘤药物研发
搜索文档
BeiGene(BGNE) - 2025 Q2 - Earnings Call Transcript
2025-08-06 21:02
BeOne Medicines (BGNE) Q2 2025 Earnings Call August 06, 2025 08:00 AM ET Company ParticipantsDaniel Maller - VP - Investor RelationsJohn Oyler - Co-Founder, Chairman & CEOAaron Rosenberg - CFOLai Wang - Global Head of R&DMatt Shaulis - General Manager - North AmericaMark Lanasa - SVP & Chief Medical Officer - Solid TumorsSean Laaman - Executive DirectorYigal Nochomovitz - DirectorXiaobin Wu - President & COOReni Benjamin - Managing DirectorConference Call ParticipantsJessica Fye - MD & Equity Research Analy ...
德琪医药(06996) - 自愿公告希维奥在中国获批用於多发性骨髓瘤的二线治疗
2025-07-28 16:45
产品管线 - 德琪医药建立9款临床到商业化各阶段肿瘤药物产品管线[4] - 6款产品有全球权益，3款有亚太权益[4] 审批进展 - 中国国家药监局批准希维奥®用于特定骨髓瘤患者[2] - 在美国及亚洲获31个临床批件(IND)[4] - 在11个亚太市场递交新药上市申请(NDA)[4] 上市情况 - 希维奥®获多个地区新药上市批准[4]